Previsão

Não temos dados de analistas para esta empresa.

Notícias Ir para o feed de notícias

Basilea partner Asahi Kasei starts phase II study of Cresemba in children in Japan

Asahi Kasei Therapeutics has begun a multicenter phase II study in Japan to investigate the safety and pharmacokinetics of the antifungal Cresemba (isavuconazole) in children at increased risk of serious fungal infections. Cresemba is already approved in Japan for adults and, in the US, Canada, Europe and China, also for children; a pediatric approval in Japan is still pending. Worldwide Cresemba sales amounted to USD 782 million in April 2025–March 2026, a 27% increase from the prior year. » Mais em finanzen.net
Basilea raises 2026 guidance after strong first half

Basilea reports H1 2026 revenue up 14% to 119 million CHF and operating profit up 32% to 31.6 million CHF; net profit was 27.9 million CHF and net cash doubled to 105 million CHF. Drivers were strong Cresemba sales and higher licensing and other income; Cresemba product sales are around $782 million (+27% over 12 months). The company raised its full-year forecast and now expects about 15% revenue growth and roughly 40% growth in operating profit for 2026. The stock rose about 8.7% in premarket trading to $58.9, near the 52-week high. » Mais em de.investing.com
Basilea Pharmaceutica raises outlook after strong H1 figures

Basilea Pharmaceutica reported a strong first half of 2026: sales rose 14% to CHF 119m, net profit climbed 77% to CHF 30m and operating profit increased about 32% to CHF 32m, driven by robust demand for Cresemba. Management significantly raised full‑year targets and now expects revenue growth of around 15% (instead of ~10%) and operating profit growth of about 40% (instead of ~20%). In addition, the Phase‑3 program for Fosmanogepix is proceeding as planned, supporting the near‑term commercial potential of the pipeline; the stock jumped sharply and approached its 52‑week high. » Mais em de.investing.com

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2013, BASILEA PHARMA já distribuiu € 4,08 em dividendos. A última distribuição ocorreu em junho de 2013.

Dados financeiros da empresa

No último trimestre, BASILEA PHARMA registou receitas de € 128,91 mi e um ganho líquido de € 30,28 mi

(EUR)	junho de 2026	YoY
Receitas	128,91 mi	-
Ganho bruto	112,2 mi	-
Ganho líquido	30,28 mi	-
EBITDA	37,13 mi	-

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 867,65 mi
Número de ações	12,38 mi
Máximo/mínimo de 52 semanas	€ 72,12 - € 47,41
Dividendos	Não
Beta	0,43
PER (PE Ratio)	15,52
PEG (PEG Ratio)	-1,28
P/VC (PB Ratio)	5,04
P/V (PS Ratio)	3,31

Perfil da empresa

Basilea Pharmaceutica AG, ein biopharmazeutisches Unternehmen im kommerziellen Stadium, konzentriert sich auf die Entwicklung von Produkten, die den medizinischen Bedarf in den Therapiebereichen Onkologie und Antiinfektiva decken. Das Unternehmen bietet Cresemba an, ein intravenös und oral zu verabreichendes Azol-Antimykotikum zur Behandlung von invasiver Aspergillose und Mukormykose in den Vereinigten Staaten und der Europäischen Union sowie in Phase III der klinischen Studien für invasive Pilzinfektionen in Japan. Das Unternehmen bietet auch Zevtera an, ein Antibiotikum zur Behandlung von ambulant und im Krankenhaus erworbener Lungenentzündung, das sich in klinischen Phase-III-Studien zur Behandlung von akuten bakteriellen Haut- und Hautstrukturinfektionen sowie von Staphylococcus-aureus-Bakteriämie befindet. Darüber hinaus entwickelt Basilea Pharmaceutica Derazantinib, einen niedermolekularen Inhibitor, der sich in der Phase 2 der klinischen Prüfung für Gallengangskrebs sowie in der Phase ½ der klinischen Prüfung für Blasen- und Magenkrebs befindet, sowie Lisavanbulin, ein Tumor-Checkpoint-Controller-Medikament. Basilea Pharmaceutica AG wurde im Jahr 2000 gegründet und hat ihren Hauptsitz in Basel, Schweiz.